T. Rowe Price Associates
PHVS icon

T. Rowe Price Associates’s Pharvaris PHVS Stock Holding History

T. Rowe Price Associates’s Portfolio PHVS Stock Details PHVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Sell
358,270
-83,986
-19% -$2.54M ﹤0.01% 1282
2026
Q1 		$12.5M Sell
442,256
-499,349
-53% -$13.3M ﹤0.01% 1163
2025
Q4 		$26.1M Buy
941,605
+124,797
+15% +$3.01M ﹤0.01% 1002
2025
Q3 		$20.4M Buy
816,808
+49,493
+6% +$1.1M ﹤0.01% 1055
2025
Q2 		$13.5M Buy
767,315
+181,228
+31% +$2.92M ﹤0.01% 1057
2025
Q1 		$9.2M Buy
586,087
+142,191
+32% +$2.4M ﹤0.01% 1129
2024
Q4 		$8.51M Buy
443,896
+118,408
+36% +$2.44M ﹤0.01% 1178
2024
Q3 		$6.03M Sell
325,488
-259,783
-44% -$4.75M ﹤0.01% 1242
2024
Q2 		$11M Sell
585,271
-172,644
-23% -$3.51M ﹤0.01% 1094
2024
Q1 		$17.5M Sell
757,915
-84,783
-10% -$2.25M ﹤0.01% 1005
2023
Q4 		$23.6M Buy
+842,698
New +$17.1M ﹤0.01% 916

Other funds holding PHVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

T. Rowe Price Associates's PHVS Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Pharvaris (PHVS) stake by 19% in Q2 2026, selling an estimated $2.54M and leaving 358,270 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1282.

T. Rowe Price Associates first reported a position in PHVS in Q4 2023 and has held it in 11 quarters since. The position peaked at $26.1M in Q4 2025. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

  • T. Rowe Price Associates held 358,270 shares of Pharvaris worth $12.4M as of Q2 2026.
  • T. Rowe Price Associates sold 83,986 Pharvaris shares in Q2 2026, an estimated $2.54M.
  • Pharvaris made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1282 holding.
  • T. Rowe Price Associates first reported a position in Pharvaris in Q4 2023 and has held it in 11 quarters since.
  • T. Rowe Price Associates's Pharvaris position peaked at $26.1M in Q4 2025.
  • 125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.